The company plans to expand its management in the US.
MicroRNA company Rosetta Genomics Ltd. (Nasdaq:ROSG) today announced that CFO Tamir Kazaz "has resigned to pursue other interests".
Rosetta added that the planned acquisition of Pennsylvania-based Parkway Clinical Laboratories and the anticipated launch of its first three products in the US would expand its focus from R&D into a full commercial entity and that, as a result, "the company expects to increase its senior management presence in the US."
In a separate development, Rosetta announced that it would collaborate with the Rabin Medical Center (Beilinson Hospital) to develop microRNA-based diagnostics in the fields of oncology, gynecology, and obstetrics.
Rosetta has a market cap of $59 million.
Published by Globes [online], Israel business news - www.globes-online.com - on June 26, 2008
© Copyright of Globes Publisher Itonut (1983) Ltd. 2008